**Patient Discharge Summary**

**Patient Information:**

* Name: John Doe
* Date of Birth: March 12, 1995
* Admission Date: February 10, 2023
* Discharge Date: February 22, 2023
* Chief Complaint: Polydipsia, polyuria, and blurred vision
* Diagnosis: Type 1 Diabetes Mellitus

**Admission and Initial Evaluation:**

John Doe, a 27-year-old male, was admitted to the endocrinology unit on February 10, 2023, with a chief complaint of polydipsia, polyuria, and blurred vision. He reported a 2-month history of increasing thirst and urine production, accompanied by frequent urination, especially at night. He also experienced blurred vision and numbness in his hands and feet. His family history is significant for type 1 diabetes in his younger sister.

**Initial Laboratory Results:**

* Fasting plasma glucose (FPG) level: 450 mg/dL (25 mmol/L)
* Glycosylated hemoglobin (HbA1C) level: 12.1%
* Complete Blood Count (CBC): Within normal limits
* Electrolyte Panel: Within normal limits
* Liver Function Tests (LFTs): Within normal limits

**Diagnostic Workup:**

The patient underwent an oral glucose tolerance test (OGTT) on February 12, 2023, which revealed a 2-hour plasma glucose level of 350 mg/dL (19.4 mmol/L). The diagnosis of type 1 diabetes was confirmed based on the patient's symptoms, laboratory results, and OGTT.

**Medical Treatment:**

The patient was started on insulin therapy with a basal-bolus regimen, consisting of:

* Lantus (insulin glargine) 10 units once daily at bedtime
* NovoLog (insulin aspart) 10 units before meals, adjusted based on pre-meal glucose levels

**Additional Medications:**

* Metformin (500 mg twice daily) for glycemic control
* Aspirin (81 mg once daily) for cardiovascular prophylaxis

**Dietary and Lifestyle Recommendations:**

The patient was counseled on a personalized meal plan, focusing on whole foods, high-quality carbohydrates, and portion control. He was advised to aim for a daily carbohydrate intake of 45-60 grams at each meal. He was also encouraged to engage in regular physical activity, aiming for at least 150 minutes of moderate-intensity exercise per week.

**Education and Monitoring:**

The patient received education on the causes of diabetes, symptoms and signs of hypoglycemia and hyperglycemia, and diabetic complications. He was instructed on proper insulin injection techniques, blood glucose monitoring, and management of hypoglycemia. He was also advised to schedule regular follow-up appointments with his primary care physician and endocrinologist.

**Discharge Instructions:**

The patient was discharged on February 22, 2023, with the following instructions:

* Continue insulin therapy as prescribed
* Monitor blood glucose levels at least 4 times daily and adjust insulin doses accordingly
* Adjust dietary intake based on blood glucose levels and insulin doses
* Schedule follow-up appointments with primary care physician and endocrinologist
* Report any symptoms of hypoglycemia or hyperglycemia to healthcare providers immediately

**Follow-up Care:**

The patient will be followed up in the endocrinology clinic in 2 weeks for a glucose monitoring appointment and will be re-evaluated for diabetic complications in 6 months.

**Conclusion:**

John Doe was diagnosed with type 1 diabetes mellitus and received insulin therapy, metformin, and aspirin. He was counseled on dietary and lifestyle modifications and received education on diabetes management. He will require ongoing monitoring and follow-up care to manage his disease and prevent complications.